![[Leu5]-Enkephalin, amide acetate](/ProductImageEN1/2024-11/Large/88a1451d-ffd1-41af-9bac-906c345c2f72.png)
![[Leu5]-Enkephalin, amide acetate](/ProductImageEN1/2024-11/Small/88a1451d-ffd1-41af-9bac-906c345c2f72.png)
[Leu5]-Enkephalin, amide acetate NEW
| Price | $32 | $47 | $67 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: [Leu5]-Enkephalin, amide acetate | Purity: 99.36% |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | [Leu5]-Enkephalin, amide acetate |
| Description | [Leu5]-Enkephalin, amide acetate is a δ opioid receptor agonist. |
| In vitro | [Leu5]-Enkephalin causes concentration-dependent, reversible inhibition of pelvic nerve-evoked contractions, with an IC50 of 2.1 nM.[1] |
| In vivo | Levels of [Leu5]-Enkephalin are significantly increased in the nucleus raphe magnus (NRM) of rats 2 weeks after the injection of complete Freund's adjuvant (CFA) (1.02±0.2 pmol/mg protein) as compared with saline-treated rats (0.49±0.04 pmol/mg protein; p<0.01). Tissue levels of [Leu5]-Enkephalin are uniformly increased in the caudal ventrolateral periaqueductal gray (PAG) 4 hr (1.15±0.25 pmol/mg protein), 4 d (1.16±0.18 pmol/mg protein), and 2 weeks (1.18±0.17 pmol/mg protein) after the injection of CFA as compared with saline-treated rats (0.55±0.03 pmol/mg protein; p<0.05, all times). A smaller increase in the levels of [Leu5]-Enkephalin occurred in the rostral aspect of the ventrolateral PAG at all time points. Finally, levels of [Leu5]-Enkephalin are also increased in the contralateral microcellular tegmental nucleus 4 d after the injection of CFA (0.53±0.04 pmol/mg protein) compared with levels in saline-treated rats (0.38±0.02 pmol/mg protein; p<0.05)[2]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | [Leu5]Enkephalin, amide acetate | [Leu5]-Enkephalin, amide Acetate | [Leu-5]-Enkephalin, amide acetate | [Leu5] Enkephalin, amide acetate |
| Inhibitors Related | Docusate sodium | Bevenopran | Mirtazapine | (-)-Menthol | Matrine | Progesterone | Naltrexone hydrochloride | Trimebutine | Mianserin hydrochloride | Amentoflavone |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Peptide Compound Library | NO PAINS Compound Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
![[Met5]-Enkephalin, amide TFA](https://img.chemicalbook.com/ProductImageEN1/2024-11/Large/82dcff0a-334e-4118-bc60-3fcfefa56b3f.png)
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $40.00/10mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $60.00/1kg |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-11-28 | |
| $126.00/1g |
Baoji Guokang Healthchem co.,ltd
|
2021-06-04 | ||
| $3.00/3KG |
VIP7Y
|
Career Henan Chemical Co
|
2019-07-11 | |
| $51.00/10mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY